Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RO6836191 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part 1: Placebo (PL) | PLACEBO_COMPARATOR | - |
| Part 1: Single Ascending Doses (SAD) of RO6836191 | EXPERIMENTAL | - |
| Part 2: PL: Low-salt (LS) followed by normal-salt (NS) diet | PLACEBO_COMPARATOR | - |
| Part 2: PL: NS followed by LS diet | PLACEBO_COMPARATOR | - |
| Part 2: RO6836191: LS followed by NS diet | EXPERIMENTAL | - |
| Part 2: RO6836191: NS followed by LS diet | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| LS followed by NS diet condition | OTHER | LS diet period followed by NS diet period |
| NS followed by LS diet condition | OTHER | NS diet period followed by LS diet period |
| Placebo | DRUG | Single oral administrations |
| RO6836191 | DRUG | Orally administered, single ascending doses |
Inclusion Criteria: * Healthy male volunteers, aged 18 to 45 years old. * No active or chronic disease following a detailed medical and surgical history and complete physical examination. * A BMI between 18 to 30 kg/m2 inclusive. * Use of a highly effective form of birth control for the duration of...
RO6836191 is an investigational small molecule being developed by Roche Holding AG for the treatment of atherosclerosis, a cardiovascular condition characterized by the buildup of plaque in the arteries. It is currently in Phase 1 clinical development.
RO6836191 is being developed by Roche Holding AG, which trades under the ticker RHHBY. The drug is an investigational small molecule intended for the treatment of atherosclerosis and is currently in Phase 1 clinical trials.
RO6836191 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied for its safety, pharmacokinetics, and pharmacodynamics in healthy volunteers.
RO6836191 has one completed clinical trial, identified as NCT01995383. This was a Phase 1, single ascending dose study that investigated the safety, pharmacokinetics, and pharmacodynamics of RO6836191 in healthy male volunteers. The trial enrolled 88 participants and was conducted in the United States.
RO6836191 is the primary name for this investigational drug. No alternative names have been reported for this compound. It is being developed by Roche Holding AG for the treatment of atherosclerosis.